دورية أكاديمية
أعرض في EDS

International survey on invasive lobular breast cancer identifies priority research questions.

التفاصيل البيبلوغرافية
العنوان: International survey on invasive lobular breast cancer identifies priority research questions.
المؤلفون: Oesterreich S; University of Pittsburgh, Department of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, Women's Cancer Research Center, Magee Womens Research Institute, Pittsburgh, PA, USA. oesterreichs@upmc.edu., Pate L; Independent ILC Advocate, Founder LBCA, Pittsburgh, PA, USA., Lee AV; University of Pittsburgh, Department of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, Women's Cancer Research Center, Magee Womens Research Institute, Pittsburgh, PA, USA.; Institute for Precision Medicine, University of Pittsburgh and UPMC, Pittsburgh, PA, USA., Chen F; University of Pittsburgh, Department of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, Women's Cancer Research Center, Magee Womens Research Institute, Pittsburgh, PA, USA.; Tsinghua University, Beijing, China., Jankowitz RC; University of Pennsylvania and Penn Medicine Abramson Cancer Center, Philadelphia, PA, USA., Mukhtar R; University of California, San Francisco, Department of Surgery, San Francisco, CA, USA., Metzger O; Dana Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA., Sikora MJ; Dept. of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Li CI; Fred Hutchinson Cancer Center, Division of Public Health Sciences, Seattle, WA, USA., Sotiriou C; Jules Bordet Institute Belgium, Brussels, Belgium., Shah OS; University of Pittsburgh, Department of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, Women's Cancer Research Center, Magee Womens Research Institute, Pittsburgh, PA, USA., Koorman T; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., Ulaner G; Molecular Imaging and Therapy, Hoag Family Cancer Institute, Molecular Imaging and Therapy, Irvine, CA. Departments of Radiology and Translational Genomics, University of Southern California, Los Angeles, CA, USA., Reis-Filho JS; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; AstraZeneca, GAITHERSBURG, MARYLAND, USA., Davidson NM; Fred Hutchinson Cancer Center, Division of Public Health Sciences, Seattle, WA, USA., Van Baelen K; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium., Hutcheson L; Lobular Breast Cancer Alliance Inc., White Horse Beach, MA, USA., Freeney S; Lobular Ireland, Dublin, Ireland., Migyanka F; Dynami Foundation, Wausau, WI, USA., Turner C; Lobular Breast Cancer UK, Nottingham, UK., Derksen P; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., Bear T; Department of Family Medicine, University of Pittsburgh, Pittsburgh, patients/advocates, Pittsburgh, PA, USA., Desmedt C; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.
المصدر: NPJ breast cancer [NPJ Breast Cancer] 2024 Jul 20; Vol. 10 (1), pp. 61. Date of Electronic Publication: 2024 Jul 20.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: New York, NY : Breast Cancer Research Foundation : Nature Publishing Group, [2015]-
مستخلص: There is growing awareness of the unique etiology, biology, and clinical presentation of invasive lobular breast cancer (ILC), but additional research is needed to ensure translation of findings into management and treatment guidelines. We conducted a survey with input from breast cancer physicians, laboratory-based researchers, and patients to analyze the current understanding of ILC, and identify consensus research questions. 1774 participants from 66 countries respondents self-identified as clinicians (N = 413), researchers (N = 376), and breast cancer patients and advocates (N = 1120), with some belonging to more than one category. The majority of physicians reported being very/extremely (41%) to moderately (42%) confident in describing the differences between ILC and invasive breast cancer of no special type (NST). Knowledge of histology was seen as important (73%) and as affecting treatment decisions (51%), and most agreed that refining treatment guidelines would be valuable (76%). 85% of clinicians have never powered a clinical trial to allow subset analysis for histological subtypes, but the majority would consider it, and would participate in an ILC clinical trials consortium. The majority of laboratory researchers, reported being and very/extremely (48%) to moderately (29%) confident in describing differences between ILC and NST. They reported that ILCs are inadequately presented in large genomic data sets, and that ILC models are insufficient. The majority have adequate access to tissue or blood from patients with ILC. The majority of patients and advocates (52%) thought that their health care providers did not sufficiently explain the unique features of ILC. They identified improvement of ILC screening/early detection, and identification of better imaging tools as top research priorities. In contrast, both researchers and clinicians identified understanding of endocrine resistance and identifying novel drugs that can be tested in clinical trials as top research priority. In summary, we have gathered information from an international community of physicians, researchers, and patients/advocates that we expect will lay the foundation for a community-informed collaborative research agenda, with the goal of improving management and personalizing treatment for patients with ILC.
(© 2024. The Author(s).)
References: Mod Pathol. 2022 Dec;35(12):1812-1820. (PMID: 35922548)
Cancer Res. 2014 Mar 1;74(5):1463-74. (PMID: 24425047)
Cancer Discov. 2018 Apr;8(4):498-515. (PMID: 29610289)
Sci Rep. 2018 Oct 18;8(1):15454. (PMID: 30337563)
Cancer. 2017 Aug 15;123(16):3015-3021. (PMID: 28382636)
Nat Cancer. 2023 Apr;4(4):535-549. (PMID: 37038006)
Cancers (Basel). 2021 Jul 22;13(15):. (PMID: 34359596)
J Nucl Med. 2021 Mar;62(3):326-331. (PMID: 32680923)
Cancer Res. 2022 Oct 17;82(20):3673-3686. (PMID: 35950920)
Clin Cancer Res. 2018 Oct 15;24(20):5165-5177. (PMID: 29941485)
Ann Oncol. 2012 Nov;23(11):2859-2865. (PMID: 22745216)
Cell. 2015 Oct 8;163(2):506-19. (PMID: 26451490)
Nat Cancer. 2023 Apr;4(4):516-534. (PMID: 36927792)
Cell Death Differ. 2016 Sep 1;23(9):1483-92. (PMID: 27035620)
Breast Cancer Res. 2021 Jan 7;23(1):6. (PMID: 33413533)
J Clin Oncol. 2015 Sep 1;33(25):2772-9. (PMID: 26215945)
Healthcare (Basel). 2023 Mar 03;11(5):. (PMID: 36900751)
J Natl Cancer Inst. 2022 Nov 14;114(11):1511-1522. (PMID: 36239760)
J Pathol Clin Res. 2022 Mar;8(2):191-205. (PMID: 34889530)
Breast Cancer Res. 2015 Feb 08;17:16. (PMID: 25757734)
Biomedicines. 2023 May 03;11(5):. (PMID: 37239021)
Mol Cancer Res. 2022 Sep 2;20(9):1405-1419. (PMID: 35665642)
NPJ Breast Cancer. 2022 Dec 6;8(1):129. (PMID: 36473870)
Ann Oncol. 2022 Aug;33(8):769-785. (PMID: 35605746)
معلومات مُعتمدة: P30 CA008748 United States CA NCI NIH HHS; P30 CA047904 United States CA NCI NIH HHS; P50 CA247749 United States CA NCI NIH HHS
تواريخ الأحداث: Date Created: 20240720 Latest Revision: 20240727
رمز التحديث: 20240727
مُعرف محوري في PubMed: PMC11271268
DOI: 10.1038/s41523-024-00661-3
PMID: 39033157
قاعدة البيانات: MEDLINE
الوصف
تدمد:2374-4677
DOI:10.1038/s41523-024-00661-3